Sun Pharmaceutical Industries Ltd. announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis. Sun Pharma's clinical study in India included 115 patients of moderate-to- severe plaque psoriasis.
A 75% skin clearance (75% reduction in Psoriasis Area Severity Index Score) was seen in 62.3%, 83.3% and 93.9% patients, respectively at weeks 12, 16, 28. A 90% skin clearance (90% reduction in Psoriasis area Severity Index Score) was saw in 26.3%, 50%, & 78.1% patients, respectively at Week 12, 16 & 28. Patients received 3 subcutaneous injections of Tildrakizumab over a period of 16 weeks (Day 1, Week 4 & Week 16) and were followed for a period of 28 weeks.
Significant improvements were also observed on additional efficacy endpoints such as, Dermatology Life Quality Index (DLQI) score. Tildrakizumab was well tolerated by Indian patients, with no immunogenicity concerns observed in this study. ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque Psoriasis9.
Patients living with moderate-to-severe plaque PSoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that ILUMYA is a sustainable choice for patients over the long term. Plaque psoriasis is a chronic autoimmune disease that causes the cells to reproduce very quickly. It's a type of psoriasis that causes thick, scaly patches called plaques on the skin.
Consequently, there is a clear unmet need for targeted therapies that deliver high, sustained skin clearance with favourable safety, minimal monitoring burden and simplified dosing to support durable disease control and improve overall quality of life for Indian patients. ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYATM is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The U.S. Food and Drug Administration (FDA) is a global global portfolio of innovative medicines.
